Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054.

about

Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054.

P2860

Q55440574-664E3F6F-C364-4158-BB0F-997362B25CCB

P2860

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054.

Item

http://www.wikidata.org/entity/Q55243180

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Discovery and preclinical char ...... monoclonal antibody LY3300054.

@en

Discovery and preclinical char ...... monoclonal antibody LY3300054.

@nl

type

Item

label

Discovery and preclinical char ...... monoclonal antibody LY3300054.

@en

Discovery and preclinical char ...... monoclonal antibody LY3300054.

@nl

prefLabel

Discovery and preclinical char ...... monoclonal antibody LY3300054.

@en

Discovery and preclinical char ...... monoclonal antibody LY3300054.

@nl

P1476

Discovery and preclinical char ...... monoclonal antibody LY3300054.

@en

P2093

Amelie Forest

http://www.w3.org/2001/XMLSchema#string

Andreas Sonyi

http://www.w3.org/2001/XMLSchema#string

Anthony Pennello

http://www.w3.org/2001/XMLSchema#string

Carmine Carpenito

http://www.w3.org/2001/XMLSchema#string

Dale L Ludwig

http://www.w3.org/2001/XMLSchema#string

Darin Chin

http://www.w3.org/2001/XMLSchema#string

David Surguladze

http://www.w3.org/2001/XMLSchema#string

Douglas Burtrum

http://www.w3.org/2001/XMLSchema#string

George Wang

http://www.w3.org/2001/XMLSchema#string

Gerald Hall

http://www.w3.org/2001/XMLSchema#string

P2860

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

The PD-1 pathway in tolerance and autoimmunity

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

Molecular mechanisms of T cell co-stimulation and co-inhibition

The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors

Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab

Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy.

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation.

P2888

s40425-018-0329-7

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S40425-018-0329-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-04-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1103687708

http://www.w3.org/2001/XMLSchema#string

P698

29712568

http://www.w3.org/2001/XMLSchema#string

P932

5925824

http://www.w3.org/2001/XMLSchema#string

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054.

about

P2860

P2860

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P932